Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.

ABSTRACT:

Purpose

Bispecific antibodies (BsAbs) have emerged as a leading drug class for cancer therapy and are becoming increasingly of interest for therapeutic applications. As of April 2020, over 123 BsAbs are under clinical evaluation for use in oncology (including the two marketed BsAbs Blinatumomab and Catumaxomab). The majority (82 of 123) of BsAbs under clinical evaluation can be categorized as bispecific immune cell engager whereas a second less well-discussed subclass of BsAbs targets two tumor-associated antigens (TAAs). In this review, we summarize the clinical development of dual TAAs targeting BsAbs and provide an overview of critical considerations when designing dual TAA targeting BsAbs.

Methods

Herein the relevant literature and clinical trials published in English un

SUBMITTER: Huang S 

PROVIDER: S-EPMC7679314 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature